Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of MBX is 59 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell